The present disclosure encompasses solid state forms of Camlipixant, in embodiments crystalline polymorphs of Camlipixant, processes for preparation thereof, and pharmaceutical compositions thereof.
The present disclosure encompasses solid state forms of Mirdametinib, particularly to Mirdametinib complexes. In embodiments the present disclosure encompasses processes for preparation thereof, and pharmaceutical compositions thereof.
C07C 259/10 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
A61K 31/21 - Esters, e.g. nitroglycerine, selenocyanates
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
6.
SOLID STATE FORMS OF MAVACAMTEN AND PROCESS FOR PREPARATION THEREOF
The present disclosure encompasses a solid state form of Mavacamten, in embodiments a crystalline polymorph of Mavacamten, processes for preparation thereof, and pharmaceutical compositions thereof.
C07D 239/545 - Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
7.
SOLID STATE FORMS OF ELACESTRANT AND PROCESSES FOR PREPARATION THEREOF
The present disclosure encompasses a solid state form of Elacestrant dihydrobromide, processes for preparation thereof, and pharmaceutical compositions thereof.
C07C 217/84 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
The present disclosure encompasses solid state forms of Ixazomib Citrate and pharmaceutical compositions thereof. Also disclosed are processes for preparation of Ixazomib Citrate.
The present disclosure encompasses a process for chiral resolution of racemic amines, particularly ethyl 2-(4-((tert-butoxycarbonyl)amino)phenyl)piperidine-3-carboxylate, into its desired isomer, ethyl (2R,3S)-2-(4-((tert-butoxycarbonyl)amino)phenyl)-piperidine-3-carboxylate, which is an intermediate useful in the synthesis of Avacopan.
The present invention relates to a process for the preparation of highly pure enantiomer of Fezolinetant, and in particular highly pure (R)-Fezolinetant. The invention also relates to chiral resolution by acid for the preparation of highly pure R-Fezolinetant. Additionally, the invention relates to a process for preparing intermediates useful for the preparation of (R)-Fezolinetant, their uses and a process for preparing (R)-Fezolinetant. In particular, the intermediate (R)-3-methylpiperazin-2-one is prepared by reductive amination with an imine reductase from Myxococcus stipitatus and ethylene diamine and ethyl pyruvate.
The present disclosure relates to solid state forms of Voclosporin and salts thereof, processes for preparation thereof and pharmaceutical compositions thereof.
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
13.
SOLID STATE FORMS OF ZIPALERTINIB HYDROCHLORIDE AND PROCESS FOR PREPARATION THEREOF
The present disclosure encompasses solid state forms of Zipalertinib hydrochloride, in embodiments crystalline polymorphs of Zipalertinib hydrochloride, processes for preparation thereof, and pharmaceutical compositions thereof.
The present disclosure relates to Lorundrostat solid state forms, in embodiments crystalline polymorphs or salts of Lorundrostat, particularly Lorundrostat hydrobromide, processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
C07D 253/07 - 1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
15.
PROCESS FOR PREPARATION OF GLP-1 PEPTIDES AND DUAL GLP-1/GIP PEPTIDES HAVING CONTROLLED PARTICLE SIZE
The present disclosure relates to processes for preparation of a peptide powder, and the preparation of peptide particles, for example a GLP-1 peptide such as Liraglutide, Dulaglutide, Exanetide, Lixisenatide and/or Semaglutide, and/or a salt thereof; particularly Liraglutide and Semaglutide and salts thereof; preferably Semaglutide and salts thereof, and more preferably Semaglutide or a Dual GIP/GLP-1 peptide such as Tirzepatide. More specifically, the disclosure relates to a process comprising spray drying of a solution comprising the peptide using an ultrasonic nozzle. The disclosure further relates to GLP-1 peptides, particularly wherein the GLP-1 peptide is selected from Liraglutide, Dulaglutide, Exanetide, Lixisenatide and/or Semaglutide, and/or a salt thereof; preferably selected from Liraglutide and Semaglutide, and a salt thereof; and more preferably Semaglutide and a salt thereof, and most preferably Semaglutide, obtainable by said process and its use in medicine and cosmetic treatment.
The present disclosure encompasses solid state forms of Trilaciclib citrate salt, in embodiments polymorphs of Trilaciclib citrate salt, processes for preparation thereof, and pharmaceutical compositions thereof.
The present disclosure encompasses solid state forms of LX9211, salts and cocrystals thereof, in embodiments processes for preparation thereof, and pharmaceutical compositions thereof.
The present disclosure encompasses solid state forms of Gusacitinib, in embodiments crystalline polymorphs of Gusacitinib, processes for preparation thereof, and pharmaceutical compositions thereof.
The present disclosure relates to Deutivacaftor solid state forms, processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
C07B 59/00 - Introduction of isotopes of elements into organic compounds
C07D 215/56 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
20.
CRYSTALLINE FORMS OF TRILACICLIB AND TRILACICLIB SALTS
The present disclosure encompasses solid state forms of Trilaciclib and Trilaciclib citrate salt, in embodiments poly-morphs of Trilaciclib and Trilaciclib citrate salt, processes for preparation thereof, pharmaceutical compositions and uses thereof.
The present disclosure encompasses solid state forms of Linerixibat, in embodiments crystalline polymorphs of Linerixibat, processes for preparation thereof, and pharmaceutical compositions thereof.
C07D 281/10 - Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
The present disclosure encompasses solid state forms of Samuraciclib and/or of Samuraciclib salts, in embodiments crystalline polymorphs of Samuraciclib and/or of Samuraciclib salts, processes for preparation thereof, and pharmaceutical compositions thereof.
The present disclosure relates to Danicopan solid state forms, processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
24.
SOLID STATE FORMS OF BELUMOSUDIL AND BELUMOSUDIL SALTS
The present disclosure encompasses solid state forms of Belumosudil, in embodiments crystalline polymorphs of Belumosudil or salts thereof, processes for preparation thereof, and pharmaceutical compositions thereof.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
25.
SOLID STATE FORMS OF BELUMOSUDIL AND BELUMOSUDIL SALTS
The present disclosure encompasses solid state forms of Belumosudil, in embodiments crystalline polymorphs of Belumosudil or salts thereof, processes for preparation thereof, and pharmaceutical compositions thereof.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
26.
SOLID STATE FORMS OF LOTILANER AND PROCESS FOR PREPARATION THEREOF
The present disclosure encompasses a solid-state form of Lotilaner, in embodiment processes for preparation thereof, and pharmaceutical compositions thereof. The present disclosure further encompasses Lotilaner salts and their solid state forms, as well as processes for preparation thereof, and pharmaceutical compositions thereof.
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
C07D 263/58 - BenzoxazolesHydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
A61K 31/423 - Oxazoles condensed with carbocyclic rings
28.
SOLID STATE FORMS OF BUNTANETAP AND PROCESS FOR PREPARATION THEREOF
The present disclosure encompasses solid state forms of Buntanetap, in embodiments crystalline polymorphs of Buntanetap or salts of Buntanetap, particularly Buntanetap tartrate, processes for preparation thereof, and pharmaceutical compositions thereof.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
The present disclosure encompasses solid state forms of Nirogacestat salts, in embodiments crystalline polymorphs of Nirogacestat salts, processes for preparation thereof, and pharmaceutical compositions thereof.
A61K 31/417 - Imidazole-alkylamines, e.g. histamine, phentolamine
C07D 233/64 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
31.
SOLID STATE FORMS OF ENSIFENTRINE AND PROCESS FOR PREPARATION THEREOF
The present disclosure encompasses solid state forms of Ensifentrine, in embodiments crystalline polymorphs or salts of Ensifentrine, particularly Ensifentrine ethane-1.2-disulfonate, processes for preparation thereof, and pharmaceutical compositions thereof.
The present disclosure encompasses solid state forms of Vericiguat, in embodiments crystalline polymorphs of Vericiguat, processes for preparation thereof, and pharmaceutical compositions thereof.
The present disclosure encompasses solid state forms of Bavdegalutamide, in embodiments crystalline polymorphs or salts or co-crystals of Bavdegalutamide, processes for preparation thereof, and pharmaceutical compositions thereof.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61P 35/04 - Antineoplastic agents specific for metastasis
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
35.
SOLID STATE FORMS OF SABIZABULIN AND PROCESS FOR PREPARATION THEREOF
The present disclosure encompasses solid state forms of Sabizabulin, in embodiments crystalline polymorphs or salts of Sabizabulin, processes for preparation thereof, and pharmaceutical compositions thereof. (Formula I)
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
36.
SOLID STATE FORMS OF ANLOTINIB AND PROCESS FOR PREPARATION THEREOF
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
37.
SOLID STATE FORMS OF DELGOCITINIB AND PROCESS THEREOF
The present disclosure relates to Delgocitinib solid state forms, processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
The present disclosure relates to processes for preparation of a peptide powder, and the preparation of peptide particles, for example a Dual GIP/GLP-1 peptide such as Tirzepatide. More specifically, the disclosure relates to a process comprising lyophilizing a solution comprising the peptide; and particle size reduction of the obtained lyophilizate. The disclosure further relates to Dual GIP/GLP-1 peptides, particularly Tirzepatide, obtainable by said process and its use in medicine and cosmetic treatment.
The present disclosure relates to solid state forms of Telatinib and Telatinib mesylate, processes for their preparation, and pharmaceutical compositions thereof (I).
The present disclosure relates to solid state forms of Telatinib and Telatinib mesylate, processes for their preparation, and pharmaceutical compositions thereof (I).
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
Solid state forms of Abexinostat salts and of Abexinostat tosylate:p-toluenesulfonic acid monohydrate complex, processes for preparation thereof, pharmaceutical compositions and uses thereof are disclosed.
C07D 307/85 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
C07C 309/04 - Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
C07C 309/05 - Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing at least two sulfo groups bound to the carbon skeleton
C07C 309/30 - Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
The present disclosure encompasses crystalline polymorphs of Rigosertib Sodium, processes for preparation thereof, and pharmaceutical compositions thereof.
C07C 317/28 - SulfonesSulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
The present disclosure encompasses salts and solid-state forms of Elenestinib, processes for preparation thereof and pharmaceutical compositions thereof.
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61P 35/02 - Antineoplastic agents specific for leukemia
44.
PROCESS FOR PREPARATION OF SOTORASIB AND SOLID STATE FORM THEREOF
The present disclosure relates to a process for the preparation of Sotorasib and salts thereof useful as a pharmaceutical active compound. The present disclosure also relates to intermediates for the preparation of Sotorasib and salts thereof. Further, the present disclosure encompasses solid state forms of Sotorasib, in embodiments crystalline polymorphs of Sotorasib, processes for preparation thereof, and pharmaceutical compositions thereof. Also provided are processes for the preparation of Sotorasib.
The present disclosure encompasses a solid state form of Centanafadine HCl, processes for preparation thereof, and pharmaceutical compositions thereof.
C07D 209/52 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
46.
SOLID STATE FORMS OF LANIFIBRANOR AND PROCESS FOR PREPARATION THEREOF
The present disclosure encompasses solid state forms of Lanifibranor, in embodiments crystalline polymorphs of Lanifibranor, processes for preparation thereof, and pharmaceutical compositions thereof.
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/428 - Thiazoles condensed with carbocyclic rings
47.
Solid state forms of mavacamten and process for preparation thereof
The present disclosure encompasses solid state forms of Mavacamten, in embodiments crystalline polymorphs of Mavacamten, processes for preparation thereof, and pharmaceutical compositions thereof.
The present disclosure encompasses solid state forms of Brilaroxazine, in embodiments crystalline polymorphs or salts of Brilaroxazine, particularly Brilaroxazine hydrochloride, processes for preparation thereof, and pharmaceutical compositions thereof.
The present disclosure encompasses solid state forms of Aficamten, in embodiments crystalline polymorphs of Aficamten, processes for preparation thereof, and pharmaceutical compositions thereof.
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 9/00 - Drugs for disorders of the cardiovascular system
01 - Chemical and biological materials for industrial, scientific and agricultural use
35 - Advertising and business services
Goods & Services
(1) Bulk pharmaceutical chemicals and fine chemicals for use in the manufacture of pharmaceuticals; chemical and chemical preparations for use in the manufacture of pharmaceuticals. (1) Business management and business management consulting; public relations; business marketing consulting; promotion services, namely, promoting the goods and services of others through dissemination of advertising materials on the internet; business research services; providing business information to others in the field of pharmaceuticals.
51.
SOLID STATE FORMS OF ZIPALERTINIB AND PROCESS FOR PREPARATION THEREOF
The present disclosure encompasses solid state forms of Zipalertinib, and of Zipalertinib complexes, in embodiments crystalline polymorphs of Zipalertinib and of Zipalertinib complexes, processes for preparation thereof, and pharmaceutical compositions thereof.
01 - Chemical and biological materials for industrial, scientific and agricultural use
35 - Advertising and business services
Goods & Services
Bulk pharmaceutical chemicals and fine chemicals for use in the manufacture of pharmaceuticals; chemical and chemical preparations for use in the manufacture of pharmaceuticals. Business management and business management consulting; public relations; business marketing consulting; promotion services, namely, promoting the goods and services of others through dissemination of advertising materials on the internet; business research services; providing business information to others in the field of pharmaceuticals.
01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
Business management and business management consulting; public relations; business marketing consulting; promotion services, namely, promoting the goods and services of others through dissemination of advertising materials on the internet; business research services; providing business information to others in the field of pharmaceuticals. Bulk pharmaceutical chemicals and fine chemicals for use in the manufacture of pharmaceuticals; chemicals and chemical preparations for use in the manufacture of pharmaceuticals.
54.
NOVEL TRILACICLIB INTERMEDIATES, METHOD OF PREPARATION AND USE THEREOF
Aspects of the present disclosure provide novel intermediates that may be used for synthesis of Trilaciclib, pharmaceutically acceptable salts or derivatives thereof. Aspects of the present disclosure also relate to a method for preparation of Trilaciclib intermediates. Further aspects of the present disclosure relate to method for preparation of Trilaciclib, pharmaceutically acceptable salts and derivatives thereof. Still further aspects of the present disclosure are drawn towards use of the Trilaciclib intermediates for the production of Trilaciclib, pharmaceutically acceptable salts or derivatives thereof.
C07D 239/24 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
The present disclosure encompasses solid state forms of Tideglusib, in embodiments crystalline polymorphs or salts or co-crystals of Tideglusib, processes for preparation thereof, and pharmaceutical compositions thereof.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A61P 37/00 - Drugs for immunological or allergic disorders
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
The present disclosure encompasses solid state forms of Cilofexor and salts thereof, in embodiments crystalline polymorphs of Cilofexor and salts thereof, processes for preparation thereof, and pharmaceutical compositions thereof.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
58.
PROCESSES FOR THE PREPARATION OF ZANUBRUTINIB AND INTERMEDIATES THEREOF
The present disclosure encompasses solid state forms of Belumosudil, in embodiments crystalline polymorphs of Belumosudil or salts thereof, processes for preparation thereof, and pharmaceutical compositions thereof.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 223/14 - Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
The present disclosure encompasses solid state forms of Denifanstat, in embodiments crystalline polymorphs of Denifanstat, processes for preparation thereof, and pharmaceutical compositions thereof.
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
The present disclosure encompasses Mesdopetam salts, solid state forms of Mesdopetam and salts thereof, in embodiments processes for preparation thereof and pharmaceutical compositions thereof.
C07C 317/22 - SulfonesSulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
01 - Chemical and biological materials for industrial, scientific and agricultural use
35 - Advertising and business services
Goods & Services
(1) Bulk pharmaceutical chemicals and fine chemicals for use in the manufacture of pharmaceuticals; chemical and chemical preparations for use in the manufacture of pharmaceuticals. (1) Business management and business management consulting; public relations; business marketing consulting; promotion services, namely, promoting the goods and services of others through dissemination of advertising materials on the internet; business research services; providing business information to others in the field of pharmaceuticals.
01 - Chemical and biological materials for industrial, scientific and agricultural use
35 - Advertising and business services
Goods & Services
Bulk pharmaceutical chemicals and fine chemicals for use in the manufacture of pharmaceuticals; chemical and chemical preparations for use in the manufacture of pharmaceuticals. business management and business management consulting; public relations; business marketing consulting; promotion services, namely, promoting the goods and services of others through dissemination of advertising materials on the internet; business research services; providing business information to others in the field of pharmaceuticals.
01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
Business management and business management consulting; public relations; business marketing consulting; promotion services, namely, promoting the goods and services of others through dissemination of advertising materials on the internet; business research services; providing business information to others in the field of pharmaceuticals Bulk pharmaceutical chemicals and fine chemicals for use in the manufacture of pharmaceuticals; chemicals and chemical preparations for use in the manufacture of pharmaceuticals
66.
SOLID STATE FORMS OF ERDAFITINIB SALTS AND PROCESSES FOR PREPARATION OF ERDAFITINIB
The present disclosure relates to solid state forms of Erdafitinib salts, processes for preparation thereof, processes for preparation of Erdafitinib and pharmaceutical compositions thereof.
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07F 7/18 - Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
67.
SOLID STATE FORMS OF PALTUSOTINE AND PROCESS FOR PREPARATION THEREOF
The present disclosure encompasses solid state forms of Paltusotine, in embodiments crystalline polymorphs of Paltusotine or salts of Paltusotine, particularly Paltusotine monomesylate and Paltusotine hemimesylate, processes for preparation thereof, and pharmaceutical compositions thereof.
C07D 401/02 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
The present disclosure encompasses solid state forms of Pralsetinib and of Pralsetinib salts and co-crystals, in embodiments crystalline polymorphs of Pralsetinib, Pralsetinib salts and co-crystals processes for preparation thereof, and pharmaceutical compositions thereof. The present disclosure encompasses solid state forms of Pralsetinib and of Pralsetinib salts and co-crystals, in embodiments crystalline polymorphs of Pralsetinib, Pralsetinib salts and co-crystals processes for preparation thereof, and pharmaceutical compositions thereof.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
69.
SOLID STATE FORMS OF TRILACICLIB AND OF TRILACICLIB SALTS
The present disclosure encompasses solid state forms of Trilaciclib and of Trilaciclib salts, in embodiments crystalline polymorphs of Trilaciclib and of Trilaciclib salts, processes for preparation thereof, and pharmaceutical compositions thereof.
The present disclosure encompasses solid state forms of Resmetirom, in embodiments crystalline polymorphs of Resmetirom, processes for preparation thereof, and pharmaceutical compositions thereof.
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
71.
SOLID STATE FORMS OF GEFAPIXANT AND PROCESS FOR PREPARATION THEREOF
The present disclosure encompasses solid state forms of Gefapixant, in embodiments crystalline polymorphs or salts or co-crystals of Gefapixant, processes for preparation thereof, and pharmaceutical compositions thereof.
Solid state forms of SEP-363856 HBr, SEP-363856 Fumarate, SEP-363856 R-camsylate and SEP-363856 S-camsylate and processes for preparation thereof, and pharmaceutical compositions thereof.
The present disclosure encompasses solid state forms of AT-001, in embodiments crystalline polymorphs of AT-001 or salts or co-crystals of AT-001, processes for preparation thereof, and pharmaceutical compositions thereof.
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
The present disclosure encompasses solid state forms and co-crystals of Ensartinib and of Ensartinib salts, in embodiments crystalline polymorphs of Ensartinib and of Ensartinib salts and co-crystals, processes for preparation thereof, and pharmaceutical compositions thereof.
The present disclosure encompasses solid state forms of AMG-510 (Sotorasib), in embodiments crystalline polymorphs of AMG-510, processes for preparation thereof, and pharmaceutical compositions thereof.
The present disclosure encompasses novel solid state forms of Aprocitentan, Aprocitentan salts and Aprocitentan co-crystals, processes for preparation thereof, and pharmaceutical compositions thereof.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
The present disclosure relates to solid state forms of Voclosporin and salts thereof, processes for preparation thereof and pharmaceutical compositions thereof.
The present disclosure encompasses solid state forms of Belumosudil, in embodiments crystalline polymorphs of Belumosudil or salts thereof, processes for preparation thereof, and pharmaceutical compositions thereof.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
80.
Solid state forms of Mitapivat and process for preparation thereof
Solid state forms of Mitapivat, Mitapivat hemisulfate, Mitapivat HCl, Mitapivat phosphate, Mitapivat hemisulfate:ascorbic acid and Mitapivat hemisulfate:adipic acid, processes for preparation thereof, pharmaceutical compositions thereof, and uses thereof are disclosed.
The present disclosure encompasses solid state forms of Avasopasem manganese, in embodiments crystalline polymorphs of Avasopasem manganese, processes for preparation thereof, and pharmaceutical compositions thereof.
The present disclosure encompasses a novel solid state form of Blarcamesine and salts thereof, processes for preparation thereof, and pharmaceutical compositions thereof.
The present disclosure encompasses solid state forms of Lucerastat, in embodiments crystalline Lucerastat: L-Pyroglutamic acid, crystalline Lucerastat: Salicylic acid, crystalline Lucerastat: Fumaric acid, crystalline Lucerastat: Benzoic acid and crystalline Lucerastat: o-Acetylsalicylic acid, solid state form thereof, processes for preparation thereof, and pharmaceutical compositions thereof.
The present disclosure encompasses solid state forms of Setogepram, in embodiments crystalline polymorphs or salts of Setogepram, particularly Setogepram sodium, processes for preparation thereof, and pharmaceutical compositions thereof.
The present disclosure encompasses crystalline polymorphs of Rivoceranib and Rivoceranib mesylate (Apatinib mesylate), processes for preparation thereof, and pharmaceutical compositions thereof.
The present disclosure relates to Plinabulin solid state forms, Plinabulin salts including hydrochloride and solid state forms thereof, processes for preparation thereof and pharmaceutical compositions thereof.
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
87.
SOLID STATE FORMS OF RISDIPLAM AND PROCESS FOR PREPARATION THEREOF
The present disclosure encompasses solid state forms of Risdiplam, including crystalline polymorphs of Risdiplam, processes for preparation thereof, and pharmaceutical compositions thereof.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
88.
UNHYDROUS CRYSTALLINE FORM OF OMECAMTIV MECARBIL DIHYDROBROMIDE SALT
The present disclosure relates to an anhydrous crystalline form (I) of omecamtiv mecarbil (CK-1827452, methyl 4-[[2-fluoro-3-[(6-methylpyridin-3-y])carbamoylamino]phenyl]methyl]piperazinyl- carboxylate) dihydrobromide salt 2 HBr, characterized by the XRPD pattern of figure 1 having peaks at 7.1, 15.0, 18.3, 18.8, 19.3, 20.3, 21.0, 21.5, 24.6 and 26.4 degrees 2-theta ± 0.2 degrees 2-theta. Omecamtiv mecarbil is a cardiac-specific myosin activator used for the treatment of heart failure.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 213/75 - Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
The present disclosure relates to solid state forms of Tafamidis and salts thereof, processes for preparation thereof and pharmaceutical compositions thereof.
The present disclosure provides solid state forms of Relugolix, crystalline forms of Relugolix, pharmaceutical compositions thereof, and pharmaceutical formulations thereof. Methods for producing these forms of Relugolix, pharmaceutical compositions, and pharmaceutical formulations are also provided.
The present disclosure relates to solid state forms of Acalabrutinib, processes for the preparation thereof and pharmaceutical compositions comprising said solid state forms of Acalabrutinib.
The present disclosure relates to solid state forms of baloxavir marboxil, processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(1H)-isoquinolinyl)ethyl]phenyl}-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl]-4-oxo-4H-chromene-2-carboxamide and of its mesylate salt
The present disclosure relates to solid state forms of Encequidar (previously referred to as HM-30181A) base, Encequidar ((HM-30181A) mesylate, co-crystals of Encequidar (HM-30181A) mesylate, processes for preparation thereof, as well as pharmaceutical compositions including the same.
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present disclosure relates to cocrystals/salts of baricitinib, processes for preparation thereof as well as a pharmaceutical composition comprising the same.
Solid state forms of Valbenazine, Valbenazine salts, processes for preparation thereof and pharmaceutical compositions thereof are disclosed. Processes for the preparation of Valbenazine and intermediates in the preparation thereof are further described.
C07D 455/06 - Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberineAlkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberineAlkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems
C07C 53/126 - Acids containing more than four carbon atoms
C07C 309/04 - Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
C07C 309/30 - Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
The present disclosure relates to Ribociclib solid state forms, Ribociclib salts including Ribociclib succinate and solid state forms thereof, as well as processes for preparation thereof and pharmaceutical compositions thereof.
The present disclosure relates to solid state forms of Lumateperone besylate and Lumateperone tosylate:R-(−)-mandelic acid, to various intermediates, to processes for their preparation and the preparation of Lumateperone or salt thereof, to pharmaceutical compositions and their use for the treatment of central nervous system disorders.
The present disclosure relates to solid state forms of Lumateperone besylate and Lumateperone tosylate:R-(−)-mandelic acid, to various intermediates, to processes for their preparation and the preparation of Lumateperone or salt thereof, to pharmaceutical compositions and their use for the treatment of central nervous system disorders.
C07C 309/29 - Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
The present disclosure relates to solid state forms of Reproxalap salts, processes for the preparation thereof, pharmaceutical formulations/compositions thereof, and methods of use thereof.
The present disclosure encompasses crystalline polymorphs of Rigosertib Sodium, processes for preparation thereof, and pharmaceutical compositions thereof.
C07C 317/28 - SulfonesSulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
